OOIR: Observatory of International Research

Papers

(The H4-Index of Bone Marrow Transplantation is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation	237
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission	131
Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes	76
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation	65
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency	62
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study	61
When is a chimaera not a chimaera?	59
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma	58
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China	55
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen	54
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease	52
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma	51
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)	49
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	48
Randomized phase 2 study of digital life coaching during transplantation for myeloma	47
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study	44
Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11	42
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study	40
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)	38
Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients	37
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients	37
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey	37
Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence	36
Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study	35
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany	34

Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation	33
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status	32
Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin	31
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peri	29
Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy	29